Improving Outcomes of Necrotising Otitis Externa
Launched by UNIVERSITY OF OXFORD · Jun 25, 2021
Trial Information
Current as of April 26, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding a condition called Necrotising Otitis Externa (NOE), which is a serious ear infection that can cause significant problems if not treated properly. The study is taking place at multiple locations in the UK and is currently active but not enrolling new participants. Researchers are looking at adult patients who are 18 years and older and have a clinical diagnosis of possible NOE, especially if they have had or will have a CT scan (a type of imaging test) as part of their regular medical care.
To participate in this trial, individuals must not have had a previous diagnosis of NOE and should be receiving their CT scan at one of the study sites. Participants can expect to be part of a thorough observation process that helps doctors understand and improve the treatment of this condition. This study aims to gather valuable information to enhance patient outcomes and care for those affected by NOE.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥ 18 years old).
- • Clinical diagnosis of possible NOE for whom CT imaging is requested or has been done as part of routine clinical care.
- Exclusion Criteria:
- • Any previous clinical diagnosis of NOE.
- • CT performed or due to be performed at hospital other than recruiting study site.
About University Of Oxford
The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Oxford, Oxfordshire, United Kingdom
Patients applied
Trial Officials
Susanne Hodgson, PhD
Principal Investigator
University of Oxford
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials